Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02974738 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) to Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Completion pushed from Sep 8, 2026 to Oct 8, 2026 · Eligibility criteria expanded, about 23 words · Publications: details revised at 2 of 2 entries Show 3 more changesShow less
    • Completion pushed from Sep 8, 2026 to Oct 8, 2026
    • Eligibility criteria expanded, about 23 words
    • Publications: details revised at 2 of 2 entries
  2. Completion date: Apr 14, 2027 to Sep 8, 2026v27
  3. Completion date: Apr 14, 2025 to Apr 14, 2027v26
  4. Completion date: Apr 14, 2023 to Apr 14, 2025v25
  5. Re-verified, no change to tracked fieldsv24
Show 22 earlier versionsHide 22 earlier versions
  1. Enrollment target: estimated 123 to confirmed 120 Primary completion date changed from estimate of Apr 14, 2023 to Jan 12, 2018 · Study sites shortened, about 64 wordsv23 Show 2 more changesShow less
    • Primary completion date changed from estimate of Apr 14, 2023 to Jan 12, 2018
    • Study sites shortened, about 64 words

    See this version in full on ClinicalTrials.gov ↗

  2. Re-verified, no change to tracked fieldsv22
  3. Study title expanded, about 1 wordv21 See this version in full on ClinicalTrials.gov ↗
  4. Enrollment target: 125 to 123 Interventions: PT2977 (Drug) to Belzutifan (Drug) · Eligibility criteria expanded, about 24 words · Study description revised · 1 morev20 Show 4 more changesShow less
    • Interventions: PT2977 (Drug) to Belzutifan (Drug)
    • Eligibility criteria expanded, about 24 words
    • Study description revised
    • Study title expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Recruiting to Active, Not Recruitingv19
  6. Study sites revised (8)v18 See this version in full on ClinicalTrials.gov ↗
  7. Site details revised at 1 of 8 sitesv17
  8. Study sites: 10 to 8v16
  9. Re-verified, no change to tracked fieldsv15
  10. Primary and study completion dates: Apr 2023 to Apr 14, 2023 Start date: Dec 2016 to Dec 7, 2016v14 Show 1 more changeShow less
    • Start date: Dec 2016 to Dec 7, 2016
  11. Primary completion date: Dec 2019 to Apr 2023 Completion date: Jun 2020 to Apr 2023v13 Show 1 more changeShow less
    • Completion date: Jun 2020 to Apr 2023
  12. Site details revised at 2 of 10 sitesv12
  13. Trial status: Active, Not Recruiting to Recruiting Site details revised at 10 of 10 sitesv11 Show 1 more changeShow less
    • Site details revised at 10 of 10 sites
  14. Trial status: Recruiting to Active, Not Recruiting Site details revised at 10 of 10 sitesv10 Show 1 more changeShow less
    • Site details revised at 10 of 10 sites
  15. Primary completion date: Dec 2018 to Dec 2019 Study sites: 9 to 10 · Completion date: Jun 2019 to Jun 2020 · Eligibility criteria expanded, about 167 words · 2 morev9 Show 5 more changesShow less
    • Study sites: 9 to 10
    • Completion date: Jun 2019 to Jun 2020
    • Eligibility criteria expanded, about 167 words
    • Study description expanded, about 10 words
    • Study arms: 3 to 4

    See this version in full on ClinicalTrials.gov ↗

  16. Site details revised at 3 of 9 sitesv8
  17. Study sites: 6 to 9v7
  18. Study sites: 4 to 6v6
  19. Study sites: 3 to 4v5
  20. Study sites: 2 to 3v4
  21. Site details revised at 1 of 2 sitesv3
  22. Trial status: Not Yet Recruiting to Recruiting Site details revised at 2 of 2 sitesv2 Show 1 more changeShow less
    • Site details revised at 2 of 2 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Merck (MSD)
407 trials monitored
See 29 trials at risk
Kidney Cancer
772 trials monitored
See 53 trials at risk
Glioblastoma
670 trials monitored
See 44 trials at risk
The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
Trial Details
NCT Number NCT02974738
Lead Sponsor Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions Advanced Solid Tumors, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, ccRCC, RCC, Clear Cell Adenocarcinoma, RCC, Kidney Cancer +8 more
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov